Oncotype DX® tests
The Oncotype DX® portfolio includes genomic cancer tests for breast cancer, colon cancer, and prostate cancer. These tests apply advanced genomic science to reveal the unique biology of an individual tumor and help support more personalized cancer treatment decisions.
The Oncotype DX® tests have helped guide treatment decisions for more than 1 million cancer patients worldwide.
The Oncotype DX Breast Recurrence Score® Assay is the only breast cancer genomic test shown to predict the likelihood of chemotherapy benefit, helping physicians and patients make more informed decisions about breast cancer treatment.
For more information, please visit http://www.oncotypedxtest.com
The Oncotype DX Breast Recurrence Score® Test for Breast Cancer
The Oncotype DX Breast Recurrence Score test provides a genomic-based, comprehensive, individualized risk assessment for early-stage invasive breast cancer in adjuvant and neoadjuvant settings.
READ MORE
Why Choose the Oncotype DX Breast Recurrence Score® Test?
The Oncotype DX Breast Recurrence Score® Test brings clarity to breast cancer treatment decisions by helping physicians and patients understand whether chemotherapy is likely to provide additional benefit.
READ MORE
The Oncotype DX® Colon Recurrence Score™ Assay
The Oncotype DX® Colon Recurrence Score™ Assay is a clinically validated genomic test that helps quantify the risk of recurrence in patients with stage II MMR-P colon cancer and selected stage IIIA/IIIB colon cancer.
READ MORE